Last updated on August 2018

Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis


Brief description of study

Primary Objective:

To evaluate, in comparison with placebo, the efficacy of SAR156597 administered subcutaneously for 24 weeks on skin fibrosis in patients with dcSSc.

Secondary Objectives:

  • To evaluate the efficacy of SAR156597 compared to placebo on physical/functional disability in patients with dcSSc.
  • To evaluate the efficacy of SAR156597 compared to placebo on respiratory function in patients with dcSSc.
  • To evaluate the safety profile of SAR156597 compared to placebo in patients with dcSSc.
  • To evaluate the potential for immunogenicity (anti-drug antibodies [ADA] response) of SAR156597 in patients with dcSSc.
  • To evaluate the pharmacokinetics (PK) (trough plasma concentrations) of SAR156597 administered subcutaneously for 24 weeks.

Detailed Study Description

The total study duration per patient will be 39 weeks; consisting of a 4-week screening, a 24-week of study treatment period, and a 11-week follow-up with no study drug treatment.

Clinical Study Identifier: NCT02921971

Contact Investigators or Research Sites near you

Start Over

Trial Transparency email recommended (Toll ...

Investigational Site Number 6420002
Targu Mures, Romania

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.